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Purpose: Bladder pain syndrome is a chronic disease that manifests as bladder pain, frequency, nocturia, and urgency. Gabap-
entin, amitriptyline, and nonsteroidal anti-inflammatory drugs are efficacious treatments for bladder pain syndrome. Here, we 
assessed the effect of triple therapy with these drugs in women with bladder pain syndrome.
Methods: Between May 2007 and May 2010, we conducted a prospective nonrandomized study on 74 patients with bladder 
pain syndrome. Of these patients, 38 (11 men and 27 women; mean age, 55.9 years; range, 25 to 77 years; mean follow-up, 12.6 
months) were administered the interstitial cystitis (IC) symptom scales (O’Leary-Sant Symptom Index) and visual analog scale 
(VAS) 1, 3, and 6 months after treatment to assess the efficacy of triple therapy.
Results: The pretreatment O’Leary-Sant IC symptom score was 11.7, and the post-treatment scores were 4.4, 3.8, and 4.0 at 1, 3, 
and 6 months, respectively; the pretreatment problem index score was 10.5, and the post-treatment scores were 3.7, 2.7, and 2.9 
at 1, 3, and 6 months, respectively. The pretreatment VAS score was 6.7, and the post-treatment scores were 1.8, 1.5, and 1.7 at 1, 
3, and 6 months, respectively. The O’Leary-Sant IC symptom index and problem index and VAS scores improved considerably 1 
month after treatment (P<0.05). However, the results at 1, 3, and 6 months after treatment were not significantly different 
(P>0.05).
Conclusions: Triple therapy was sufficiently effective in patients with bladder pain syndrome and caused no significant adverse 
effects. However, large-scale studies should be performed to verify our findings.
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INTRODUCTION
Bladder pain syndrome/interstitial cystitis (BPS/IC) is defined 
as unpleasant sensations such as pain, pressure, and discomfort 
perceived in relation to the bladder and lower urinary tract, with 
symptoms lasting for 6 weeks or longer in the absence of infec-
tion or any other confirmed causes [1]. The prevalence of BPS/
IC varies greatly by nation, race, and definition, but the occur-
rence rate is approximately 0.3%, with BPS/IC being 10 to 20% 
less frequent among men than women. In some population-
based studies that used questionnaires, however, BPS/IC was 30 
to 50 times more frequent [1,2].
  Although various etiologies are suggested, no clear clinical or 
pathological cause of BPS/IC has been identified, and there is 
no certain diagnosis or treatment. It is important to reassure the 
patient that the symptoms, although bothersome, are not signs 
of a life-threatening disease. Patient education and empower-
ment is an important initial step in therapy. In the absence of 
disease progression, treatment should focus on reducing symp-
tom severity. Some patients get better naturally and even heal 
completely within a few weeks or months. Those patients who 
experience persistent, unacceptable symptoms despite reassur-
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ance and conservative treatment are candidates for more aggres-
sive modalities. These might include oral and/or intravesical 
therapy, neuromodulation, treatment with pain killers or narcot-
ic analgesics, and surgical intervention [1,3].
  In terms of drug treatments, tricyclic antidepressants, anti-
convulsants, and analgesics (nonsteroidal anti-inflammatory 
drugs [NSAIDs]) have been used on their own or in combina-
tion. Amitriptyline is an effective tricyclic antidepressant that 
suppresses the reuptake of serotonin and noradrenalin at pre-
synaptic nerve ends and the anticholinergic reaction of the cen-
tral nervous system and peripheral nerves, which in turn leads 
to sedation due to an antihistamine reaction in the central ner-
vous system. The analgesic effect occurs at a dose of 25 to 150 
mg per day and shows a good response within 30 to 50% [3-5]. 
Gabapentin is a structural analogue of γ-aminobutyric acid; it 
was first introduced as an anticonvulsant in 1994 and has been 
effectively used in various chronic pain treatments and is espe-
cially good for treating neuropathic pains [6-8].
  Although there are some reports on the usefulness of gabap-
entin, amitriptyline, and NSAIDs, there are limitations to using 
a single drug to effectively control and treat a patient’s pain. 
Therefore, in this study, we aimed to understand the effects and 
influences of a triple therapy of gabapentin, amitriptyline, and 
an NSAID by using the O’Leary-Sant Symptom Index and vi-
sual analog scale (VAS).
MATERIALS AND METHODS
We reviewed the records of patients who visited the urology 
clinic at our hospital from May 2007 to May 2010 and were di-
agnosed with BPS. Among the 74 patients who were treated with 
an NSAID, amitriptyline, and gabapentin, 38 patients were ad-
ministered the O’Leary-Sant Symptom Index and VAS. Previ-
ous or current intake of amitriptyline, NSAIDs, and gabapentin 
was considered an exclusion criterion for study enrollment. Pa-
tients were subsequently treated prospectively for 6 months with 
a self-titration protocol. They were instructed to take 600 mg 
etodolac micronized, 5 mg amitriptyline, and 300 mg gabapen-
tin at bedtime. If they were not symptom-free after 2 weeks, they 
were instructed to increase the dose to 20 mg amitriptyline and 
600 mg gabapentin and thereafter to 75 mg amitriptyline and 
900 mg gabapentin (maximum allowed doses). If the patients 
experienced satisfactory relief from their symptoms, they were 
asked to maintain the individual lowest effective dose and to 
not increase the dose further.
  In order to determine treatment effects, the O’Leary-Sant 
Symptom Index and VAS were administered before and 1, 3, 
and 6 months after treatment. The O’Leary-Sant Symptom In-
dex was divided into the IC Symptom Index and the IC Prob-
lem Index. We used SPSS ver. 13.0 (SPSS Inc., Chicago, IL, USA) 
for statistical analysis, and P-values below 0.05 were deemed 
statistically significant.
RESULTS
The subjects were 11 males and 27 females, with an average age 
of 55.9 years (range, 25 to 77 years) (Table 1). All patients com-
plained of pelvic pain, pressure, and discomfort for 6 months or 
longer (main symptom) along with at least one other urinary 
symptom such as persistent urge to void or urination frequency 
in the absence of infection or other identifiable causes. The IC 
symptom index score before treatment was 11.7, the IC prob-
lem index was 10.5, and the VAS score was 6.7; all scores were 
quite high. At 1 month after treatment, the IC symptom index 
score was 4.4, the IC problem index score was 3.7, and the VAS 
score was 1.8; i.e., the scores had improved. After 3 months of 
treatment, the scores decreased: the IC symptom index score 
was 3.8, the IC problem index score was 2.7, and the VAS score 
was 1.5. At 6 months, the scores were as follows: the IC symp-
tom index score, 4.0; the IC problem index score, 2.9; and the 
VAS score, 1.7 (Fig. 1). Complications while taking medication 
were drowsiness (n=3) and dry mouth (n=5), but not serious 
enough to stop the treatment.
  Compared with before treatment, the IC symptom index 
score improved at 1, 3, and 6 months after the treatment by 
62.4%, 67.5%, and 65.8%, respectively; the IC problem index 
score improved by 64.8%, 74.3%, and 72.4%, respectively; and 
the VAS score improved by 73.1%, 77.6%, and 74.6%, respec-
Table 1.  Baseline demographic and clinical characteristics of 
the patients according to treatment group
Characteristics
Male:Female   11:27
Age (yr) 55.9
Mean follow-up (mo) 12.6
O'Leary-Sant IC symptom index before treatment 11.7
O'Leary-Sant IC problem index before treatment 10.5
VAS before treatment 6.7
IC, interstitial cystitis; VAS, visual analog scale.258    www.einj.or.kr
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tively. The improvements were statistically significant (P<0.05). 
Comparing the three post-treatment results, however, revealed 
that the scores obtained 1 and 3 months after treatment were 
slightly better but not statistically significant. The scores ob-
tained 3 and 6 months after treatment indicated a slight deteri-
oration in symptoms, but this deterioration was not statistically 
significant (P>0.05) (Fig. 1). 
DISCUSSION
The clinical definition of BPS/IC should be expanded to include 
IC in cases with no tumor, infection, or any other identifiable 
cause of the symptoms. Chronic BPS/IC is defined as experienc-
ing an unpleasant sensation in the bladder and lower urinary 
tract symptoms such as pain, pressure, or discomfort. However, 
there is no exact clinical etiology or diagnosis for IC as yet, and 
the treatments are quite diverse, ranging from behavioral thera-
py to cystectomy [1,2].
  Pain is defined as an unpleasant sensory and emotional ex-
perience associated with actual or potential tissue damage or 
described in terms of such damage. Pain can be categorized as 
physiologic pain of the normal state and pathophysiologic pain 
of the abnormal state. Physiologic pain represents the nocicep-
tive pain that disappears as soon as the nociception input disap-
pears. Pathophysiologic pain continuously occurs, even after the 
nociception is gone or the tissue damage is repaired and can be 
further divided into inflammatory pain and neuropathic pain; 
it causes spontaneous pain, evoked pain, etc. Pathophysiologic 
pain is not a warning sign, but a pathological condition that 
harms the body, particularly if the inflammation or damage oc-
curs around or in the nerve tissues. Sensitization of the primary 
afferent sensory fibers by mediators of the pain response results 
in greater, more frequent transmission of action potentials to 
nociceptive neurons than in ‘normal’ pain responses, and cen-
tral sensitization can also cause an individual to perceive greater 
and more prolonged pain [6,7].
  NSAIDs have anti-inflammatory, analgesic, and antipyretic 
effects. Because all NSAIDs and COX-2-suppressing drugs have 
equal effects on reducing pain, they have been used to treat 
chronic pain syndrome. The most serious and common com-
plication of such NSAIDs is gastrointestinal disturbance [9].
  The effects of anticonvulsants in pain treatment were first re-
ported in the 1960s, and the anticonvulsant gabapentin was con-
firmed to reduce neuropathic pain. It is used to treat diabetic 
neuropathy, trigeminal neuralgia, pain due to cancer or multi-
ple sclerosis, dyspareunia, and BPS [10-14]. Clinically, an anti-
convulsant is effective for treating lancinating or burning pain, 
which is a type of chronic neuropathic pain. Gabapentinoids 
act as neuromodulators by selectively binding to the α2-δ-subunit 
protein of calcium channels in various regions of the brain and 
the superficial dorsal horn of the spinal cord. They also have a 
peripheral analgesic action [10-14].
  Tricyclic antidepressants are used to treat various pain syn-
dromes and cause effects such as increased pain tolerance, re-
covery of normal sleep, and decrease in depression symptoms 
[15]. They can be effective against chronic pain by directly sup-
pressing the nervous mechanisms underlying pain or by allevi-
ating depression symptoms caused by the ability to accept pain 
or experience pain. They control the activation and suppression 
of peripheral neurons or modulate the neuronal inhibitory or 
stimulatory pathways in the spine or supraspinal segments. Such 
mechanisms alleviate pain symptoms by suppressing acetylcho-
line, histamine, and the H1 receptor and by inhibiting the reup-
take of released serotonin and norepinephrine [16]. Also, anti-
depressants are reported to be generally safe drugs with bear-
able side effects and low withdrawal symptoms in most studies 
[17,18].
  Chronic pain causes more stress for a depressed patient, ag-
gravating the condition, whereas anxiety or depression may 
strengthen the pain. Depression may influence nociception by 
reducing the activity of powerful descending inhibitory path-
ways that emanate from the brainstem. Serotonergic nuclei such 
as the nucleus raphae magnus of the medulla and various cate-
Fig. 1. Changes in symptoms from baseline to 1, 3, and 6 
months. IC, interstitial cystitis; VAS, visual analog scale; Tx, 
treatment. 
a) P<0.05. 
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cholamine nuclei located in the pons descend into the spinal 
cord via the dorsal funiculus. The activity of this pathway inhib-
its nociception at the level of the dorsal horn [19-21].
  In BPS/IC patients, the independent application of NSAIDs, 
amitriptyline, and gabapentin was found to show about 30 to 
50% efficacy in most reports, indicating that treatment with in-
dividual drugs has limited effects, and when a large dose is used, 
severe adverse effects may occur. To overcome the limitations 
of single-drug treatment, we devised a multimodal therapy with 
minimal amounts of an NSAID, etravil, and gabapentin.
  Our triple therapy comprised minimal doses of the drugs, 
and we then compared scores before and after the treatment. 
The IC symptom index and IC problem index scores at 1, 3, 
and 6 months after treatment showed a 60 to 70% improve-
ment, and the VAS score improved more than 70%. These im-
provements were statistically significant. After 1 month of treat-
ment, however, the reduction in symptoms and pain were no 
longer significant. Therefore, we concluded that it is desirable to 
maintain low doses of these drugs to control the symptoms and 
pain after 1 month. If the pain goes away, the drug treatment 
should be stopped and the patient should be monitored careful-
ly. When standardizing treatment efficacy, the level of pain and 
symptom scores during treatment will be important in BPS/IC 
research.
  Our study had a few limitations. First, the number of patients 
was small, and the follow-up period was short. Such issues can 
be resolved by conducting a prospective study with more patients 
and lengthening the follow-up period. Second, in this study, be-
cause we evaluated the level of pain based on the memory of 
the patient, the responses were prone to recollection bias error. 
It is probable, however, that BPS/IC patients most sensitive to 
pain would have expressed the level of pain they experienced 
relatively better than other discomforts. Third, there was no con-
trol group. This study used the research model in which the pre-
treatment pain level of the patient was the control because it is 
ethically problematic to administer a placebo to patients with 
severe pain. 
  In determining the treatment effects for BPS/IC, the symp-
toms of the patient are used as an important index. We used the 
O’Leary-Sant Symptom Index and VAS scores before and after 
administering our triple therapy of gabapentin, amitriptyline, 
and an NSAID. The observed improvements were statistically 
significant, leading us to believe that the treatment was clinical-
ly helpful. We believe that this research objectively determined 
the effects of the triple treatment and the status of pain in BPS/
IC patients. However, prospective research that supplements 
the limitations and issues of this study should be conducted.
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